Alpha 2.0
Login Register
» Authors » Nikita Gouchie-Provencher

Nikita Gouchie-Provencher

Explore the profile of Nikita Gouchie-Provencher including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 47
Followers 0
Related Specialties
Endocrinology
General Medicine
Public Health
Top 10 Co-Authors
Ahmad Haidar
Adnan Jafar
Joanna Rutkowski
Laurent Legault
Milad Ghanbari
Michael A Tsoukas
Jean-Francois Yale
Remi Rabasa-Lhoret
Jennifer Rene
Bruce A Perkins
Published In
Diabetes Obes Metab
Diabetes Technol Ther
Diabetes Care
Lancet Digit Health
Nat Med
Affiliations
Soon will be listed here.
Recent Articles
1.
Simple meal announcements and pramlintide delivery versus carbohydrate counting in type 1 diabetes with automated fast-acting insulin aspart delivery: a randomised crossover trial in Montreal, Canada
Cohen E, Tsoukas M, Legault L, Vallis M, Von Oettingen J, Palisaitis E, et al.
Lancet Digit Health . 2024 Jun; 6(7):e489-e499. PMID: 38906614
Background: In type 1 diabetes, carbohydrate counting is the standard of care to determine prandial insulin needs, but it can negatively affect quality of life. We developed a novel insulin-and-pramlintide...
2.
A Randomized Crossover Trial to Compare Automated Insulin Delivery (the Artificial Pancreas) With Carbohydrate Counting or Simplified Qualitative Meal-Size Estimation in Type 1 Diabetes
Haidar A, Legault L, Raffray M, Gouchie-Provencher N, Jafar A, Devaux M, et al.
Diabetes Care . 2023 May; 46(7):1372-1378. PMID: 37134305
Objective: Qualitative meal-size estimation has been proposed instead of quantitative carbohydrate (CHO) counting with automated insulin delivery. We aimed to assess the noninferiority of qualitative meal-size estimation strategy. Research Design...
3.
Empagliflozin add-on therapy to closed-loop insulin delivery in type 1 diabetes: a 2 × 2 factorial randomized crossover trial
Haidar A, Lovblom L, Cardinez N, Gouchie-Provencher N, Orszag A, Tsoukas M, et al.
Nat Med . 2022 May; 28(6):1269-1276. PMID: 35551290
There is a need to optimize closed-loop automated insulin delivery in type 1 diabetes. We assessed the glycemic efficacy and safety of empagliflozin 25 mg d as add-on therapy to...
4.
Alleviating carbohydrate counting with a FiASP-plus-pramlintide closed-loop delivery system (artificial pancreas): Feasibility and pilot studies
Tsoukas M, Cohen E, Legault L, Von Oettingen J, Yale J, Vallis M, et al.
Diabetes Obes Metab . 2021 May; 23(9):2090-2098. PMID: 34047449
Aim: To assess whether a FiASP-and-pramlintide closed-loop system has the potential to replace carbohydrate counting with a simple meal announcement (SMA) strategy (meal priming bolus without carbohydrate counting) without degrading...
5.
Reducing the need for carbohydrate counting in type 1 diabetes using closed-loop automated insulin delivery (artificial pancreas) and empagliflozin: A randomized, controlled, non-inferiority, crossover pilot trial
Haidar A, Yale J, Lovblom L, Cardinez N, Orszag A, Falappa C, et al.
Diabetes Obes Metab . 2021 Feb; 23(6):1272-1281. PMID: 33528904
Aim: To assess whether adding empagliflozin to closed-loop automated insulin delivery could reduce the need for carbohydrate counting in type 1 diabetes (T1D) without worsening glucose control. Materials And Methods:...
6.
Comparison Between Closed-Loop Insulin Delivery System (the Artificial Pancreas) and Sensor-Augmented Pump Therapy: A Randomized-Controlled Crossover Trial
Haidar A, Legault L, Raffray M, Gouchie-Provencher N, Jacobs P, El-Fathi A, et al.
Diabetes Technol Ther . 2020 Oct; 23(3):168-174. PMID: 33050728
Several studies have shown that closed-loop automated insulin delivery (the artificial pancreas) improves glucose control compared with sensor-augmented pump therapy. We aimed to confirm these findings using our automated insulin...